Cubist Systematic Strategies’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $36.5K | Buy |
54,246
+6,999
| +15% | +$3.77K | ﹤0.01% | 2873 |
|
|
2025
Q2 | $25.6K | Buy |
+47,247
| New | +$28.1K | ﹤0.01% | 2821 |
|
|
2025
Q1 | – | Sell |
-456,946
| Closed | -$466K | – | 3448 |
|
|
2024
Q4 | $466K | Buy |
+456,946
| New | +$835K | ﹤0.01% | 2210 |
|
|
2024
Q3 | – | Sell |
-185,813
| Closed | -$66.6K | – | 3449 |
|
|
2024
Q2 | $66.6K | Buy |
+185,813
| New | +$100K | ﹤0.01% | 2678 |
|
|
2023
Q4 | – | Sell |
-2,173
| Closed | -$1.3K | – | 4058 |
|
|
2023
Q3 | $1.3K | Sell |
2,173
-187,743
| -99% | -$201K | ﹤0.01% | 3219 |
|
|
2023
Q2 | $247K | Buy |
189,916
+156,042
| +461% | +$213K | ﹤0.01% | 2712 |
|
|
2023
Q1 | $59.6K | Buy |
+33,874
| New | +$96.7K | ﹤0.01% | 3536 |
|
|
2022
Q4 | – | Sell |
-218,429
| Closed | -$1.07M | – | 4559 |
|
|
2022
Q3 | $1.07M | Sell |
218,429
-208,845
| -49% | -$1.07M | 0.01% | 2567 |
|
|
2022
Q2 | $1.77M | Buy |
427,274
+368,151
| +623% | +$1.59M | 0.01% | 1980 |
|
|
2022
Q1 | $344K | Sell |
59,123
-107,625
| -65% | -$640K | ﹤0.01% | 2764 |
|
|
2021
Q4 | $1.25M | Buy |
166,748
+101,404
| +155% | +$881K | 0.01% | 1749 |
|
|
2021
Q3 | $589K | Sell |
65,344
-15,110
| -19% | -$149K | 0.01% | 1916 |
|
|
2021
Q2 | $963K | Buy |
80,454
+54,899
| +215% | +$622K | 0.01% | 1596 |
|
|
2021
Q1 | $320K | Sell |
25,555
-113,543
| -82% | -$1.53M | ﹤0.01% | 2216 |
|
|
2020
Q4 | $2.17M | Buy |
139,098
+49,292
| +55% | +$577K | 0.03% | 892 |
|
|
2020
Q3 | $849K | Sell |
89,806
-34,720
| -28% | -$376K | 0.01% | 1434 |
|
|
2020
Q2 | $1.12M | Buy |
124,526
+93,552
| +302% | +$868K | 0.02% | 1111 |
|
|
2020
Q1 | $197K | Sell |
30,974
-67,426
| -69% | -$500K | 0.01% | 1738 |
|
|
2019
Q4 | $824K | Buy |
+98,400
| New | +$905K | 0.02% | 1280 |
|
|
2019
Q3 | – | Sell |
-68,478
| Closed | -$738K | – | 2444 |
|
|
2019
Q2 | $738K | Buy |
68,478
+15,205
| +29% | +$162K | 0.01% | 1215 |
|
|
2019
Q1 | $508K | Buy |
53,273
+36,735
| +222% | +$375K | 0.02% | 1192 |
|
|
2018
Q4 | $190K | Buy |
+16,538
| New | +$205K | 0.01% | 1563 |
|
|
2018
Q2 | – | Sell |
-65,087
| Closed | -$1.24M | – | 2014 |
|
|
2018
Q1 | $1.24M | Buy |
65,087
+42,917
| +194% | +$917K | 0.07% | 353 |
|
|
2017
Q4 | $364K | Buy |
22,170
+2,228
| +11% | +$33.1K | 0.02% | 1112 |
|
|
2017
Q3 | $299K | Buy |
19,942
+11,766
| +144% | +$130K | 0.02% | 1170 |
|
|
2017
Q2 | $72K | Buy |
+8,176
| New | +$52.5K | ﹤0.01% | 1499 |
|
|
2016
Q2 | – | Sell |
-2,482
| Closed | -$15K | – | 1859 |
|
|
2016
Q1 | $15K | Sell |
2,482
-1,164
| -32% | -$6.99K | ﹤0.01% | 1543 |
|
|
2015
Q4 | $33K | Sell |
3,646
-278
| -7% | -$2.14K | ﹤0.01% | 1642 |
|
|
2015
Q3 | $22K | Sell |
3,924
-3,578
| -48% | -$29.5K | ﹤0.01% | 1777 |
|
|
2015
Q2 | $83K | Buy |
7,502
+7,367
| +5,457% | +$95K | ﹤0.01% | 1646 |
|
|
2015
Q1 | $2K | Sell |
135
-2,750
| -95% | -$42.5K | ﹤0.01% | 1860 |
|
|
2014
Q4 | $44K | Sell |
2,885
-19,546
| -87% | -$237K | ﹤0.01% | 1781 |
|
|
2014
Q3 | $242K | Buy |
22,431
+12,534
| +127% | +$164K | 0.01% | 1248 |
|
|
2014
Q2 | $151K | Buy |
+9,897
| New | +$142K | 0.01% | 1251 |
|
Other funds holding SGMO
GCP
Cubist Systematic Strategies's SGMO Position: Q3 2025 in Review
Cubist Systematic Strategies increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 15% in Q3 2025, buying an estimated $3.77K and bringing the position to 54,246 shares worth $36.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2873.
Cubist Systematic Strategies first reported a position in SGMO in Q2 2014 and has held it in 34 quarters since. The position peaked at $2.17M in Q4 2020. 112 funds tracked by Wall St. Rank hold SGMO as of Q3 2025.
- Cubist Systematic Strategies held 54,246 shares of SANGAMO THERAPEUTICS INC worth $36.5K as of Q3 2025.
- Cubist Systematic Strategies bought 6,999 SANGAMO THERAPEUTICS INC shares in Q3 2025, an estimated $3.77K.
- SANGAMO THERAPEUTICS INC made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2873 holding.
- Cubist Systematic Strategies first reported a position in SANGAMO THERAPEUTICS INC in Q2 2014 and has held it in 34 quarters since.
- Cubist Systematic Strategies's SANGAMO THERAPEUTICS INC position peaked at $2.17M in Q4 2020.
- 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.